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Bovine brain 6-phosphofructo-2-kinase/fructose- 
2,6-bisphosphatase was  purified  to homogeneity and 
characterized. This bifunctional enzyme is a homodi- 
mer *ith a subunit molecular weight of 120,000, 
which is twice that of all other known bifunctional 
enzyme isozymes. The kinase/bisphosphatase activity 
ratio was 3.0. The K,,, values for  fructose 6-phosphate 
and ATP of the 6-phosphofructo-2-kinase were  27  and 
56 MM, respectively. The K,,, for  fructose 2,g-bisphos- 
phate  and  the K j  for  fructose 6-phosphate for the bis- 
phosphatase were 70 and 20 FM, respectively. Physio- 
logic concentrations of citrate had reciprocal effects on 
the enzyme’s activities, i.e. inhibiting  the  kinase (Ki of 
36 PM) and activating the bisphosphatase (KO of 16 MM). 
Phosphorylation of the  brain enzyme was catalyzed by 
the cyclic  AMP-dependent protein  kinase  with a stoi- 
chiometry of 0.9 mol  of phosphate/mol of subunit  and 
at  a rate similar to that seen with the liver isozyme. In 
contrast to the  liver isozyme, the kinetic  properties of 
the  brain enzyme were unaffected by  cyclic  AMP-de- 
pendent protein kinase phosphorylation, and also was 
not a substrate  for protein kinase C. The  brain isozyme 
formed a labeled phosphoenzyme intermediate and 
cross-reacted  with antibodies raised  against  the  liver 
isozyme. However, the NH2-terminal amino acid se- 
quence of a peptide generated by cyanogen bromide 
cleavage of the enzyme had no identity  with  any  known 
bifunctional enzyme  sequences. These results  indicate 
that a novel  isozyme, which is related to other 6-phos- 
phofructo-2-kinase/fructose-2,6-bisphosphatase iso- 
zymes, is expressed specifically in  neural tissues. 
Fructose 2,6-bisphosphate (Fru-2,6-P2)’ is the most pow- 
erful activator of 6-phosphofructo-l-kinase (EC 2.7.1.11) 
(PFK-l), a key regulatory enzyme of glycolysis. Its synthesis 
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and breakdown are catalyzed by 6-phosphofructo-2-kinase 
(EC 2.7.1.105) and fructose-2,6-bisphosphatase (EC 3.1.3.46), 
respectively (1-3). These two activities belong to separate 
domains of each subunit of the same homodimeric protein. 
This bifunctional enzyme integrates a number of metabolic 
and hormonal signals by means of allosteric effectors and 
phosphorylation/dephosphorylation processes and by its  tran- 
scription rate (1-9). 
Several mammalian 6-phosphofructo-2-kinase/fructose- 
2,6-bisphosphatase (PFK-Z/FBPase-2) isozymes have been 
described whose expression differs depending on the tissue 
(1-3,  10-14). The liver “L”  and muscle “M” isozymes  derive 
from a 55-kilobase gene by alternative splicing from two 
promoters (15). Its expression  is controlled by ubiquitous and 
tissue-specific transcription factors (16) and hormones  (6-7), 
the most important being glucocorticoids (5, 7). The heart 
“H” type contains a COOH-terminal extension that includes 
a sequence that codes  for a protein kinase C and cyclic AMP- 
dependent protein kinase (PKA) phosphorylation sites (17). 
Fru-2,6-P2 is present in various types of cultivated brain 
cells at  a concentration similar to that in hepatocytes (18), 
and  it is  also a positive allosteric effector of brain PFK-1 (19- 
20). The bisphosphorylated metabolite increases transiently, 
in parallel with fructose 1,6-bisphosphate and fructose 6- 
phosphate, during early stages of ischemia (21). It also de- 
creases during hypoglycemia  following the fall in fructose 6- 
phosphate and increases to normal levels after glucose admin- 
istration (22). In the diabetes state, Fru-2,6-P2 levels are 
decreased permitting the glucose-sparing effects of ketone 
bodies  on brain glycolysis  (23).  However, all the changes  in 
brain Fru-2,6-P2 are quantitatively low, suggesting that in 
brain tissue Fru-2,6-P2 remains remarkably constant under a 
wide variety of experimental conditions, suggesting that it 
plays a permissive  role in cerebral glycolysis, by maintaining 
PFK-1 in an active state. 
As a first step in understanding how brain Fru-2,6-P2 levels 
are regulated, we report the isolation and characterization of 
a bovine brain PFK-Z/FBPase-2 isozyme  which has unique 
kinetic and  structural properties compared to other known 
mammalian isozymes, and which is probably encoded by a 
heretofore undiscovered  gene. 
EXPERIMENTAL  PROCEDURES 
MateriaZ~-[y~~P]ATP (3000 Ci/mmol)  was from Amersham. 
Mono-Q and Superose 12 HR columns and Blue Sepharose were  from 
Pharmacia LKB Biotechnolog Inc. Enzymes and other biochemical 
reagents were purchased from either Boehringer or Sigma. Pro-Blot 
transfer membranes were from Applied Biosystems. Purified protein 
kinase C from rat brain was kindly given by Dr. E. Rozengurt 
(Imperial Cancer Research Fund, London). 
Enzyme Assays-PFK-2 activity was determined by a modification 
of the method described by Bartrons  et al. (24). Samples were incu- 
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bated at  30 "C in 50 mM Hepes buffer (pH 7.1) containing 50 mM 
KCI, 1 mM ditiothreitol, 1 mM Pi,  and, unless otherwise indicated, 5 
mM ATP, 5 mM fructose 6-phosphate (Fru-6-P),  and 17.5 mM glucose 
6-phosphate. 
FBPase-2 activity was measured by the release of 32Pi from [2-32P] 
Fru-2,6-P2 as described by Ventura et al. (23). [2-32P]Fru-2,6-P2 was 
synthesized according to El-Maghrabi et al. (25). 
Western  Blot  Analysis-Immunoblot analysis were performed es- 
sentially as described by Burnette (26) with a 1:200 dilution of the 
polyclonal antibody raised against rat liver PFK-S/FBPase-2 (27). 
Bound antibodies were detected by incubation with '2sI-labeled pro- 
tein A (1-2 X IO6 cpm/ml) for 30 min and,  after washing, exposed to 
x-ray film. 
Phosphoenzyme  Assay-Phosphoenzyme autoradiograms were ob- 
tained by a modification of El-Maghrabi et al. (27). Briefly, purified 
bovine brain PFK-2/FBPase-2 (0.5-2 pg) was incubated at  room 
temperature with 1 p~ Fru-2,6-[2-"P]P2 (1-2 X lo6 cpm/assay) in 50 
mM Hepes buffer (pH 7.5), 50 mM KCI, 2 mM MgC12, 1 mM ditioth- 
reitol. The reaction was stopped after 15 s by addition of 2 volumes 
of ice-cold 10% trichloroacetic acid. After centrifuging, the pellet was 
washed with 1% HC1 in acetone and centrifuged again. The pellet 
was then redissolved in 25 pl of 0.1 M NH4HC03 (pH 9.0), and  the 
sample was analyzed by SDS-PAGE in  a 8% gel. 
Phosphorylation of PFK-2lFBPase-2 by Cyclic AMP-dependent 
Protein Kinase and Protein Kinase C-Brain PFK-2/FBPase-2 was 
incubated for 20 min at  30 "C with the purified catalytic subunit of 
cyclic AMP-dependent protein kinase (2 milliunits/ml) in  a medium 
containing 100 mM Hepes (pH 7.11, 5 mM MgCl,, 1 mM ditiothreitol, 
and 0.5 mM [y-32P]ATP-Mg (1-2 X lo6 cpm/nmol). For the protein 
kinase  C assay, PFK-S/FBPase-2 was incubated for 20 min at  30 "C 
with protein kinase C (2 milliunits/ml) in a medium containing 100 
mM Hepes (pH 7.1), 5 mM MgC12, 1 mM ditiothreitol, 5 mM Pi, 0.5 
mM [yT2P]ATP-Mg (1 X lo6 cpm/nmol), 2 mM CaC12, 50 pg  of 
phosphatidylserine/ml, and 2 pg  of diolein/ml. After the incubation, 
phosphorylated samples were subjected to SDS-PAGE. The gel was 
then dried and exposed to x-ray film. 
Cyanogen  Bromide  Digestion and Amino  Acid  Sequencing-Blotted 
PFK-2IFBPase-2 was suspended in 100 pl of 70% formic acid, and 
CNBr was added to a final concentration of 5 mg/ml. The tube was 
flushed with nitrogen and incubated in the dark for 24 h at room 
temperature. The incubation mixture was diluted 10 times and di- 
alyzed overnight against 2 mM p-mercaptoethanol. After dialysis, 
digested PFK-Z/FBPase-2 was subjected to SDS-PAGE in a 15% 
acrylamide, 0.75% bisacrylamide gel. The gel was transferred to a 
Pro-Blot membrane (Applied Biosystems) for 45 min at 70 V in 10 
mM CAPS, 10% methanol (v/v), pH 11. The blotted membrane was 
stained with Coomassie Blue, and bands of interest were  excised and 
washed extensively with water. The amino acid sequence was deter- 
mined in  a liquid-phase sequencer (Applied Biosystems 470-A protein 
sequencer). 
Other Methods-SDS-PAGE  was carried out in a 8% gels according 
to  the procedure of Laemmli (28). Protein was determined by the 
method of Bradford (29) using bovine serum albumin as a  standard. 
Protein kinase C activity was assayed with histone 111-S as a  sub- 
strate. One unit of enzyme activity catalyzes the formation of 1 pmol 
of product per min under the specified assay conditions. 
RESULTS 
Purification of 6-Phosphofructo-2-kinase/fructose-2,6-bis- 
phosphatase-Bovine brains were obtained from a local 
slaughterhouse, maintained in ice, and used immediately. 
Cortex from dissected brains (700 g)  was trimmed away from 
meninges and blood vessels and homogenized in 3 volumes of 
ice-cold 50 mM Tris-HC1 (pH 8.0), 50 mM KC1, 2 mM EGTA, 
2 mM ditiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 1 
p M  leupeptin, 1 p M  pepstatin, 0.1 mM Fru-6-P, 0.3 mM glucose 
6-phosphate, and 3% (w/v) polyethylene glycol 6000 (PEG 
6000). The homogenate was centrifuged at  15,000 x g for 20 
min. 3% (w/v) PEG 6000  was added to  the  supernatant  and 
after 10 min it was subjected to centrifugation, and  the pellet 
was discarded. 15% PEG 6000  was added to  the  supernatant, 
the  pH was adjusted to 6.5 with HCl, and  after  standing for 
10 min it was centrifuged a t  15000 X g for 20 min. The pellet 
(6-21% PEG 6000) was redissolved in 300 ml of ice-cold  50 
mM Tris-HC1 (pH 8.0), 400 mM KCl, 2 mM ditiothreitol, 0.2 
mM phenylmethylsulfonyl fluoride, 1 p M  leupeptin, 1 p M  
pepstatin (buffer B)  and clarified by centrifugation at  15,000 
X g for 15 min. The enzyme was then applied to a Blue 
Sepharose CL6B column (1.8 X 35 cm) which had been 
equilibrated with buffer B. The column was  washed overnight 
with buffer B  until the eluate was free of protein (monitored 
by A2m).  PFK-Z/FBPase-2 was eluted (5-10 mM ATP-Mg) 
with a  linear  gradient of ATP-Mg (0-15  mM) in buffer B. The 
fractions  containing PFK-2 activity were  pooled and ultraf- 
iltered to approximately 3 ml with an Amicon concentrator 
equipped with a YM-10 filter. The concentrated enzyme was 
diluted 4-fold and applied to a Mono-Q column equilibrated 
with 50 mM Tris-HC1 (pH 8.0), 50 mM KCl, 2 mM ditiothreitol, 
0.2 mM phenylmethylsulfonyl fluoride, 1 p M  leupeptin, 1 p M  
pepstatin, and 10%  (v/v) glycerol (buffer C). After washing 
with the equilibration buffer a  continuous KC1 gradient (0- 
300 mM) made in buffer C was applied. PFK-2/FBPase-2 
eluted at  0.2 M KC1. The fractions  containing the peak activity 
were  pooled, diluted 2-fold, and reapplied in the same column. 
The enzyme eluted as a single peak with a  flatter gradient 
made in the same buffer (Fig. 1). The peak fractions  contain- 
ing the enzyme were stored frozen at  -80 "C in 20% (v/v) 
glycerol. 
This purification method permitted the isolation of bovine 
brain PFK-2FBPase-2 with an average 10% yield. The pro- 
cedure took less than 4 days to complete and led to a 15,000- 
fold purification (Table I). No other significant Fru-2,6-P* 
synthesizing activities were found during the purification 
procedure. The purified fractions displayed both  PFK-2 and 
FBPase-2 activities indicating that  the bovine brain enzyme 
is bifunctional with specific activities of 90 milliunits/mg of 
15 20 25 30 35 
Time (mln)  
FIG. 1. Elution profile from Mono-Q column and SDS- 
PAGE of bovine  brain  PFK-2IFBP-e-2. PFK-Z/FBPase-2 from 
bovine brain was reapplied into  a Mono-Q column as described under 
"Results." The enzyme was eluted between  19 and 21 min. A fraction 
of the peak  was subjected to gel electrophoresis in an 8% acrylamide 
gels. The position of molecular mass standards is indicated by the 
arrows. 
TABLE I 
Purification of PFK-2lFBPase-2 from bovine brain 
steps activitv 
PFK-2 Act. Purifica- 
tion Yield 
mg mU mUfmg -fold ?6 
Extract 25002  147  0.006 1 100 
Blue Sepharose 3.44 48.4 14.1 2345 32.9 
Mono-Q 0.71 31.6 44.5 7417 21.5 
Mono-Q reapplication 0.15 13.9 92.7 15450 9.5 
6-21% PEG 4242  82.4 0.019 3.2  56 
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protein for the kinase and 29 milliunits/mg of protein for the 
bisphosphatase. 
Molecular Weights-The M, of the  subunit was determined 
to  be 120,000 by SDS-PAGE (Figs. 1 and 2). The molecular 
weight of the  native enzyme was estimated  to be 225,000 by 
molecular filtration on a Superose 12 HR column in a 200 
mM phosphate buffer, pH 7.0. These  data  are  indicative of a 
homodimeric structure for the  brain  bifunctional enzyme. 
Western Blot and Phosphoenzyme Assays of PFK-2/ 
FBPase-2  from Brain-Purified brain  and liver  enzymes were 
subjected  to  Western  blotting  after labeling  with  Fru-2,6-[2- 
:”PIP2 (Fig. 2). The  Western  blot showed that  anti-liver  PFK- 
2/FBPase-2 polyclonal antibodies  cross-reacted  with  the 
brain form indicating  that  they  share some antigenic  relat- 
edness.  In  addition,  brain  PFK-2/FBPase-2 formed  a  labeled 
phosphoenzyme intermediate  upon brief incubation  with  Fru- 
2,6-[2-”PIP2, suggesting that  the  brain  bisphosphatase reac- 
tion involves a phosphohistidine intermediate as does the 
other  mammalian isozymes (3). 
Kinetic Properties-Several kinetic properties of bovine 
brain  PFK-2IFBPase-2 were determined  (Table 11). The K, 
values for Fru-6-P  and  ATP  are  in  the  same  range  as  those 
determined for the heart and muscle isoforms (10-11, 30). 
The K, value  for Fru-6-P (27 PM) is lower than  that of the 
liver  form (1-3). The  bisphosphatase  has a high K, value  for 
Fru-2,6-P2 (70 PM) and also showed a high sensitivity to 
noncompetitive  inhibition by Fru-6-P (86% inhibition a t  100 
PM Fru-6-P).  Citrate  had reciprocal  effects on  both activities, 
inhibiting kinase and  activating  bisphosphatase.  Citrate  re- 
kDa SDS-PAGE Western b lo t  Phosphoenzyme 
LIVER BRAIN 
FIG. 2. SDS-PAGE, Western blot, and fructose 2,6-bisphos- 
phate labeling of brain PFK-2FBPase-2. The left panel  is  the 
Coomassie  Blue stain of purified brain  PFK-2/FBPase-2.  The  center 
panel  is  the  immunoblot of brain  and liver enzymes that were per- 
formed as described under “Experimental Procedures.” The right 
panel shows SDS-PAGE electrophoresis of 3ZP-labeled brain enzyme 
with Fru-2,6-[2-”P]P2. 
TABLE I1
Kinetic  constants of bovine brain PFK-2/FBPase-P 
PFK-2 activity  was determined  as described under  “Experimental 
Procedures” except that  ATP  concentration was kept a t  5 mM and 
Fru-6-P was  varied for the  determination of K. for Fru-6-P;  Fru-6-P 
was  kept a t  5 mM and  ATP varied  for the  determination of K, for 
ATP;  ATP was kept a t  5 mM and  Fru-6-P  and  citrate were varied  for 
the determination of  Ki for citrate.  FBPase-2  activity was determined 
as described under  “Experimental  Procedures”  except that  Fru-2.6- 
Pz concentration was varied  for the  determination of the K,; Fru-2,6- 
Pz and  Fru-6-P  concentrations were varied, and  NADP, phosphoglu- 
cose isomerase, and glucose-6-phosphate  dehydrogenase were omitted 
for  the  determination of  Ki for Fru-6-P; Fru-2,6-P2  and  citrate were 
varied for the  determination of K. for citrate. 
Vmax K,,, ATP K ,  FN-6-P K, citrate 
PFK-2 90 mU/mg 55 p~ 27pM 35 p M  
Vmnx K, F1w-2.6-P~ K, FN-6-P KO citrate 
FBPase-2 29 mU/mg 70 p~ 20pM  16
duced the K, for Fru-2,6-P2 to 50% without changing the 
VmaX value of the  bisphosphatase activity. Other known mod- 
ulators of liver PFK-2/FBPase-2  such  as glycerol 3-phosphate 
or phospho(eno1)pyruvate (1-3) (up to 5 mM each) did not 
modify either kinase or  bisphosphatase activities. ATP also 
had  no effect on  the  bisphosphatase activity. 
Phosphorylation of Brain  PFK-2/FBPase-2 by Cyclic AMP- 
dependent  Protein  Kinase  and  Protein Kinase C-To analyze 
further the nature of brain PFK-2FBPase-2 the purified 
enzyme was tested,  in  parallel  with  the liver isozyme, as a 
substrate for the  catalytic  subunit of cyclic AMP-dependent 
protein  kinase  and  protein kinase C. These two protein 
kinases have been  shown to differentially  phosphorylate PFK- 
2lFBPase-2 isoforms (1-3, 31). As shown in Fig. 3, the  cata- 
lytic subunit of cyclic AMP-dependent  protein kinase cata- 
lyzed the phosphorylation of both the brain and liver iso- 
zymes. When  similar  concentrations of pure bovine brain  or 
rat liver isozymes were incubated  with  the catalytic subunit 
of cyclic AMP-dependent  protein  kinase,  their phosphoryla- 
tion was catalyzed at similar  rates (Fig. 3). The stoichiome- 
tries of phosphorylation were 0.9 mol of phosphate/mol  sub- 
unit for the  brain enzyme and 0.8 mol of phosphate/mol of 
subunit for the liver enzyme. These  results indicate a ratio 
close to 1 suggesting that  brain  PFK-2/FBPase-2  has a single 
phosphorylation site. However, unlike the heart and testes 
isozymes which are  substrates for protein kinase C, the  brain 
enzyme was not  phosphorylated by protein kinase  C (data  not 
shown).  In  agreement  with  our previous results (23),  incuba- 
tion with the catalytic subunit of cyclic AMP-dependent 
protein kinase did not  alter  the K,,, for Fru-6-P or V,,, of 
bovine brain PFK-2 at   pH 7.1, whereas it did modify the 
activity of the liver isozyme (23). In order to determine 
whether  the absence of activation could result from the fact 
that the enzyme remained in a phosphorylated form, the 
enzyme was incubated with glucose, ADP-Mg, hexokinase, 
and  the  catalytic  subunit of cyclic AMP-dependent protein 
kinase in order to remove phosphate specifically from the 
enzyme  by a reversal of the cyclic AMP-dependent protein 
kinase reaction (32). However, no change in activity was 
observed. I t  was concluded that cyclic AMP-dependent pro- 
tein  kinase catalyzed phosphorylation of the  brain enzyme 
lt 
0 1 0   2 0  3 0  
TIME (mln) 
FIG. 3. Phosphorylation of bovine brain and rat liver PFK- 
2FBPase-2 by cyclic AMP-dependent protein kinase. PFK-2/ 
FBPase-2 from ( B )  brain (0.5 p ~ )  and (L) liver (1 FM) were incubated 
in  the presence of 2  milliunits/ml catalytic  subunit of cyclic AMP- 
dependent  protein  kinase  as described under  “Experimental Proce- 
dures.” At the indicated  times, aliquots (40 pl) were removed, and  the 
amount of [“P]phosphate incorporated on bovine brain (0) or rat 
liver (0) was determined.  The values are  the means f S.E. of three 
separate experiments. The phosphorylated enzymes (20 min) were 
subjected to gel electrophoresis and autoradiographied. 
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does not affect the activity of the enzyme. 
Cyanogen Bromide Cleavage and Amino Acid  Sequencing- 
In order to obtain further  structural information  about the 
nature of the enzyme we sequenced the native  protein after 
alkylation with 4-vinylpyridine. The results showed that  the 
NH2 terminus of the protein was blocked to  Edman degrada- 
tion. PFK-2/FBPase-2 (5-10 pg) was then partially digested 
with CNBr after alkylation as described under  “Experimental 
Procedures.” The cleaved peptides were subjected to SDS- 
PAGE  in  15% acrylamide, 0.75% bisacrylamide gels. The gels 
were electroblotted and the membranes were stained with 
Coomassie Blue and washed extensively with water. Three 
major peptides were detected with molecular weights of 
36,000, 32,000, and 22,000. The blotted 36-kDa peptide (50 
pmol) was sequenced directly from the membrane with cer- 
tainty to its 10th residue. The sequence was Gln-Val-Asn- 
Gln-His-Leu-Lys-Gly-Glu-Tyr. This sequence has no signif- 
icant homology to any of the known sequences of other 
mammalian  PFK-2IFBPase-2s (13, 15, 17,33-34). 
DISCUSSION 
We report here a procedure for the isolation of PFK-2/ 
FBPase-2 from bovine brain  resulting in a 15,000-fold puri- 
fication. The enzyme was pure as judged by SDS-PAGE and 
both Coomassie Blue or silver staining  and had an average 
native molecular weight of  225,000 corresponding to  an hom- 
odimer of two M, 120,000 subunits. This subunit molecular 
weight is approximately twice that of all known mammalian 
bifunctional enzyme forms, since the liver, skeletal muscle, 
and  heart forms have molecular masses of 55,54, and 58 kDa, 
respectively (1-3,8-11,13). The homogeneous enzyme exhib- 
ited both activities, and  the kinase/bisphosphatase activity 
ratio remained constant through all purification steps  after 
the PEG  fractionation (data  not shown). The specific kinase 
activity was  90 and 29 milliunits/mg of protein for the bis- 
phosphatase. No other significant brain forms of PFK-2/ 
FBPase-2 were found during the purification procedure, 
whether cortex or whole brain was used as  the tissue source. 
Based on the above findings, the brain form represents a 
unique isozyme but is bifunctional like all other mammalian 
isozymes. 
Different mammalian tissue-specific PFK-2/FBPase-2 iso- 
zymes have been described. The liver and muscle isozymes 
differ only in the first exon, sharing the  other  13 exons (15). 
The  heart type is encoded by another gene (35) that includes 
1 2  successive exons which are similar to those of the liver/ 
skeletal muscle  gene, but the  heart gene has different exons 
at ends of the gene.The novel form expressed in brain  has 
kinetic constants for substrates  and allosteric effectors which 
are similar to those of the  other bifunctional enzymes, partic- 
ularly those of the heart form (10, 31). It shares common 
basic properties of all mammalian PFK-2/FBPase-2 such as 
homodimeric structure  and bifunctionality. It forms a  phos- 
pholabeled intermediate when incubated with Fr~-2 ,6- [2-~~P]  
Pz, which suggests a common catalytic mechanism for the 
bisphosphatase reaction (3). It also shares some common 
antigenic determinants since it cross-reacts with antisera 
raised against the liver isozyme. In addition, total RNA from 
brain strongly hybridized with a near-full-length cDNA probe 
from liver, giving a major band of  6.8 kb and a minor one of 
4 kb (23). All these properties suggest that it is a closely 
related structure to the other PFK-2IFBPase-2 isozymes. 
However, protein sequencing from a CNBr-derived peptide 
revealed no sequence homology to any other known PFK-2/ 
FBPase-2. This lack of homology  is not due to species differ- 
ences since the bovine liver and bovine heart sequences have 
recently become available (14, 17), and they show no amino 
acid identity to  the bovine brain CNBr sequence. In addition, 
the  subunit molecular weight also is about twice that of all 
other mammalian PFK-Z/FBPase-Zs, including the form re- 
cently isolated from testis which has  a molecular mass of 55 
kDa and whose mRNA is 2 kb in size (13). A bifunctional 
enzyme from yeast, with a  subunit molecular mass (93 kDa) 
of about twice that of mammalian forms, was recently cloned 
(36). This yeast enzyme has  an analogous kinase/bisphospha- 
tase domain structure  to  that found in  the mammalian forms, 
but also has  an additional extensive NH2-  and COOH-termi- 
nal sequence which has no homology to  the mammalian forms. 
In addition, the active site phosphoacceptor (His-258  in the 
rat liver form) is a  serine  in the yeast enzyme, and  this form 
is devoid of FBPase-2 activity (37). Recently, we have 
screened a bovine brain cDNA library with a human heart 
cDNA probe. A clone was isolated whose sequence revealed 
that  the brain isozyme is encoded by a  separate gene, which 
is different from those that encode the liver/skeletal muscle, 
heart,  and  testis forms, and which is specifically expressed in 
neural tissues.’ Work is in progress to define the  structural 
basis for the differences between the larger brain form and 
the smaller mammalian forms and to  ascertain  whether the 
120-kDa brain isozyme  is evolutionarily related  to the 93-kDa 
yeast enzyme. 
The concentration of Fru-2,6-Pz in mammalian tissues is 
controlled by the relative activities of PFK-2  and FBPase-2. 
The kinase/bisphosphatase activity ratio is  close to  3 for the 
brain enzyme when both  activities  are  determined  under V,,, 
conditions. However, the bisphosphatase has a very high K ,  
for its  substrate (70 PM) compared to  that of the liver enzyme 
(0.1 PM). This fact suggests that under physiological condi- 
tions  the high kinasefiisphosphatase  ratio  accounts for the 
high concentration of the bisphosphorylated metabolite found 
in  brain (5 nmol/g) despite the low enzyme concentration (18, 
21-23). In addition, the bisphosphatase would  be expected to 
be inhibited in vivo  by the concentrations of Fru-6-P normally 
found in brain (20 p ~ ) .  Since Fru-6-P is also a substrate for 
the kinase and  its cellular concentrations  are close to  the K ,  
value for PFK-2,  it is reasonable to  postulate that  the steady 
state  Fru-6-P level controls brain Fru-2,6-P2  concentration. 
An increase of Fru-6-P would result  in  a  parallel increase of 
Fru-2,6-P2 by virtue of increased kinase activity as well as 
decreased bisphosphatase  activity via noncompetitive product 
inhibitor  (Table 11). In  contrast, any  diminution of Fru-6-P 
concentration would result  in lower levels of the bisphosphor- 
ylated metabolite, which would decrease the net glycolytic 
flux. This scenario is seen during brain ischaemia or hypogly- 
cemia (21-23). These  considerations do not apply to  the  other 
substrate of the kinase activity, since the K, for ATP is 
substantially lower than  the steady state tissue  concentration 
of ATP (2-3 mM), so the enzyme would be fully saturated 
under  normal conditions. Other regulatory metabolites such 
as glycerol 3-phosphate or phospho(eno1)pyruvate which act 
as allosteric effectors on liver PFK-Z/FBPase-2 (1-3) have 
no effect on the  brain enzyme (23 and results not shown). 
However, citrate  has a reciprocal effect on  both activities. Not 
only does it inhibit the kinase, but it also activates the 
bisphosphatase by decreasing the K, for its  substrate @-fold 
activation at 5 PM Fru-2,6-P2).  Citrate, which is increased in 
diabetic animals (23, 38), may mediate the glucose sparing 
effect of ketone bodies on brain glycolysis by its effects on 
PFK-1 (39) and PFK-2 (present paper).  When available, 
ketone body metabolism in  brain increases citrate levels which 
F. Ventura, J. L. Rosa, S. Ambrosio, S. J. Pilkis, and R. Bartrons, 
manuscript in preparation. 
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inhibit directly brain PFK-1 and also decrease Fru-2,6-P2 
concentration. 
Phosphorylation/dephosphorylation mechanisms that con- 
trol the relative kinase/bisphosphatase activity ratio have 
been demonstrated for the liver isozyme (1-3). The brain 
enzyme was phosphorylated by CAMP-dependent protein ki- 
nase but, unlike the  heart  and  testis forms, it was not phos- 
phorylated by protein  kinase  C  (13,31). In  its phosphorylation 
pattern, the brain PFK-2/FBPase-2 is similar to the liver 
isozyme, even though the significance of its phosphorylation 
is unclear since the phosphorylated enzyme showed no 
changes  in  kinetic  properties (23). Therefore, the control of 
PFK-2/FBPase-2 activities depends mainly on the changes 
of substrates  and allosteric modulators. In addition,  no 
changes  in activity have been detected  in several physiological 
conditions (21-23). Since the brain enzyme has only a single 
phosphorylation  site, while its molecular weight is approxi- 
mately double that of the  other mammalian isozymes, it is 
unlikely that  the brain enzyme arose via gene duplication. It 
is possible that an additional NH2- or COOH-terminal se- 
quence prevents the transmission of the phosphorylation site 
signal to  the kinase and bisphosphatase domains. It seems 
reasonable to postulate that  the  brain isozyme has evolved to 
meet the metabolic exigencies of that tissue, that additional 
polypeptide sequence in  this form ensures regulation of brain 
Fru-2,6-Pz concentration by substrates  and effectors of the 
enzyme, and  that covalent modification induced-activity 
changes are inexpedient in this purely glycolytic tissue. 
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